CD133 has been accepted as a cancer initiating cell marker for colon cancer and it has been shown that CD133+ cellular subpopulation could be used as a baseline to sort and detect CTCs in the peripheral blood of CRC patients using FACS. The gene discussed is PROM1; the disease is malignant colon neoplasm.